Javascript must be enabled to continue!
Dexmedetomidine versus Lignocaine in the Prevention of Etomidate-induced MyoclonusA Randomised Double-blinded Study
View through CrossRef
Introduction: Etomidate is a preferred induction agent owing to its stable haemodynamic profile, minimal respiratory sideeffects, minimal histamine release, cerebral protection and its property of rapid onset and short duration. However, myoclonus has been reported as one of its side-effects which poses great concern. Amongst the various drugs used to attenuate it, the role of intravenous (i.v.) Dexmeditomidine and Lignocaine have been reported in literature to be of great success. Aim: To compare the efficacy of Dexmedetomidine and Lignocaine in preventing Etomidate-induced Myoclonus. Materials and Methods: The randomised, double blinded study included 104 adult consented patients, of either sex, American Society of Anaesthesiology (ASA) I and II, aged 18-65 years, undergoing routine surgery under general anaesthesia. They were randomly allocated into two groups of 52 patients each viz., Group I receiving 0.5 µg/kg of injection (inj.) Dexmedetomidine i.v. and Group II 1 mg/kg of inj. Lignocaine diluted in 10 mL normal saline i.v. The incidence and severity of myoclonus were assessed and recorded within 90 seconds after etomidate injection using a four point severity scale. The collected data were entered in Statistical Package for Social Sciences (SPSS) version 21.0. Results: Total 104 subjects with the demographic parameters such as age, sex, ASA and weight comparable between the two groups were analysed. Group I recorded lesser number of patients (17, 32.7%) to myoclonus as compared with Group II (21, 40.4%), (p-value=0.41). Maximum patients in Group I developed grade I myoclonus while in Group II, it was grade 2. No patients in Group I developed grade 3 myoclonus as against 5 patients in Group II (p-value=0.03). Conclusion: Dexmedetomidine and Lignocaine were equally effective in the prevention of Etomidate-induced myoclonus but dexmeditomedine was better because of lesser incidence of severe grade myoclonus.
Title: Dexmedetomidine versus Lignocaine in the Prevention of Etomidate-induced MyoclonusA Randomised Double-blinded Study
Description:
Introduction: Etomidate is a preferred induction agent owing to its stable haemodynamic profile, minimal respiratory sideeffects, minimal histamine release, cerebral protection and its property of rapid onset and short duration.
However, myoclonus has been reported as one of its side-effects which poses great concern.
Amongst the various drugs used to attenuate it, the role of intravenous (i.
v.
) Dexmeditomidine and Lignocaine have been reported in literature to be of great success.
Aim: To compare the efficacy of Dexmedetomidine and Lignocaine in preventing Etomidate-induced Myoclonus.
Materials and Methods: The randomised, double blinded study included 104 adult consented patients, of either sex, American Society of Anaesthesiology (ASA) I and II, aged 18-65 years, undergoing routine surgery under general anaesthesia.
They were randomly allocated into two groups of 52 patients each viz.
, Group I receiving 0.
5 µg/kg of injection (inj.
) Dexmedetomidine i.
v.
and Group II 1 mg/kg of inj.
Lignocaine diluted in 10 mL normal saline i.
v.
The incidence and severity of myoclonus were assessed and recorded within 90 seconds after etomidate injection using a four point severity scale.
The collected data were entered in Statistical Package for Social Sciences (SPSS) version 21.
Results: Total 104 subjects with the demographic parameters such as age, sex, ASA and weight comparable between the two groups were analysed.
Group I recorded lesser number of patients (17, 32.
7%) to myoclonus as compared with Group II (21, 40.
4%), (p-value=0.
41).
Maximum patients in Group I developed grade I myoclonus while in Group II, it was grade 2.
No patients in Group I developed grade 3 myoclonus as against 5 patients in Group II (p-value=0.
03).
Conclusion: Dexmedetomidine and Lignocaine were equally effective in the prevention of Etomidate-induced myoclonus but dexmeditomedine was better because of lesser incidence of severe grade myoclonus.
Related Results
Detection of “smoke powder” etomidate and its metabolite etomidate acid in blood and urine by UHPLC–MS-MS: application in authentic cases
Detection of “smoke powder” etomidate and its metabolite etomidate acid in blood and urine by UHPLC–MS-MS: application in authentic cases
Abstract
Recently, etomidate has been widely used as an alternative in illicit drug market. It is usually added to regular cigarette tobacco (commonly known as “ciga...
Duration and depth of anaesthesia after administration of a single dose of etomidate combined with remifentanil in healthy patients: a survey and a randomised controlled double-blind pilot study
Duration and depth of anaesthesia after administration of a single dose of etomidate combined with remifentanil in healthy patients: a survey and a randomised controlled double-blind pilot study
Background: Etomidate is a hypnotic agent frequently used to induce general anaesthesia, primarily in frail patients and in emergency situations. The depth of etomidate-induced gen...
Etomidate Dosing and Recovery in Cannabis Users in Wada Test
Etomidate Dosing and Recovery in Cannabis Users in Wada Test
Introduction:
The Wada test involves the intracarotid injection of anesthetics—commonly etomidate—to transiently anesthetize one hemisphere for assessing langua...
Study About the Effect of Dexmedetomidine Versus Lignocaine on Hemodynamic and Recovery Responses During Tracheal Extubation
Study About the Effect of Dexmedetomidine Versus Lignocaine on Hemodynamic and Recovery Responses During Tracheal Extubation
Introduction: During tracheal extubation, hemodynamic fluctuations can occur, such as increased heart rate and blood pressure, potentially causing adverse events. Dexmedetomidine a...
Electrocardiographic Effects of Propofol versus Etomidate in Patients with Brugada Syndrome
Electrocardiographic Effects of Propofol versus Etomidate in Patients with Brugada Syndrome
Abstract
Background
Brugada Syndrome is an inherited arrhythmogenic disease, characterized by the typical coved type ST-segment elevation in the ...
Incidence of Fever Associated With Dexmedetomidine in the Adult Intensive Care Unit
Incidence of Fever Associated With Dexmedetomidine in the Adult Intensive Care Unit
Background:
Published literature has described the temporal relationship of dexmedetomidine with elevated temperatures, but there is limited data to quantify th...
Comparison of Intravenous Sedation with Dexmedetomidine and Propofol for Breast Cancer Skin Lesion Electrochemotherapy: A Randomized, Double‐blinded Clinical Trial
Comparison of Intravenous Sedation with Dexmedetomidine and Propofol for Breast Cancer Skin Lesion Electrochemotherapy: A Randomized, Double‐blinded Clinical Trial
Background: Skin metastases occur in 5% - 30% of breast cancer patients, highlighting the need for effective treatments. Electrochemotherapy, which combines electric pulses with ch...
A Comparative Study of Dexmedetomidine-Fentanyl Versus Dexmedetomidine-Pentazocine for Monitored Anesthesia Care in Tympanoplasty
A Comparative Study of Dexmedetomidine-Fentanyl Versus Dexmedetomidine-Pentazocine for Monitored Anesthesia Care in Tympanoplasty
Background: Monitored anesthesia care (MAC) is increasingly being used in various surgical procedures due to its safety and effectiveness. Tympanoplasty, a common otological proced...

